Chairman of the Headquarters for Executing Imam Khomeini’s Order (HEIKO) Mohammad Mokhber underlined good progress in clinical trial of Iran-made coronavirus vaccine, saying that the country will reach the monthly production of 12mln doses of the vaccine in May.
>
“The process of production of Coronavirus vaccine is progressing based on plan and so far 21 people have gone under test and 14 others have also been licensed for testing since two days ago,†Mokhber told FNA on Wednesday.
He added that the first phase of the human trial of the vaccine produced by the HEIKO will be completed in nearly 3 weeks, and the second phase will begin in March.
“We will reach the production of 1.5 to 3 million doses per month within the next 15 days," Mokhber said.
“We have planned to increase the production of coronavirus vaccine to 12 to 14 million doses in May and June to resolve the problem with vaccine production completely,†he added.
Mokhber had on Tuesday said that the country is the only producer of a vaccine which is effective on the coronavirus mutations spreading in Britain and South Africa.
“The only vaccine without side effects which is efficient on the mutated coronavirus is being developed by the HEIKO,†Mokhber said.
“The Equipment has been developed to produce 100,000 vaccine doses per month,†he added.
Mokhber noted that Iran has gone through 6 different project platforms to produce coronavirus vaccine with successful results, and said, “The clinical trial of one of the vaccines has started and three more will be completed by the end of the year."
The official had last week said that the first phase of human test for COVIRAN Barekat has been successful and no side effects have been reported from the vaccine.
“Two to three million doses of the vaccine will be produced in the country by the end of the current Iranian year (March 20),†he went on to say.
The official noted that the first phase of the human trial on 21 volunteers is about to finish, and added that the vaccine will be available to the public in spring.
“It will be given to people cheaper than the foreign sample and Iran will become self-sufficient in this field,†Mokhber stressed. ■